==========
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2008; month=10; day=17; hr=11; min=1; sec=34; ms=2;]
==========

Validated By CRFValidator v 1.0.3

Application No: 10575864 Version No: 1.0

Input Set:

Output Set:

Started: 2008-09-11 17:29:17.940
Finished: 2008-09-11 17:29:20.079
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 139 ms
Total Warnings: 17
Total Errors: 7
No. of SeqIDs Defined: 17
Actual SeqID Count: 17

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
E	257	Invalid sequence data feature in <221> in SEQ ID (6)
W	213	Artificial or Unknown found in <213> in SEQ ID (7)
W	213	Artificial or Unknown found in <213> in SEQ ID (8)
E	257	Invalid sequence data feature in <221> in SEQ ID (8)
W	213	Artificial or Unknown found in <213> in SEQ ID (9)
E	257	Invalid sequence data feature in <221> in SEQ ID (9)
W	213	Artificial or Unknown found in <213> in SEQ ID (10)
W	213	Artificial or Unknown found in <213> in SEQ ID (11)
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
E	257	Invalid sequence data feature in <221> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
E	257	Invalid sequence data feature in <221> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)

Input Set:

Output Set:

Started: 2008-09-11 17:29:17.940
Finished: 2008-09-11 17:29:20.079
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 139 ms
Total Warnings: 17
Total Errors: 7
No. of SeqIDs Defined: 17
Actual SeqID Count: 17

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
E 257	Invalid sequence data feature in <221> in SEQ ID (17)

SEQUENCE LISTING

<110> FRANK, HANS-GEORG
HABERL, UDO
BRACHT, FRANZPETER
RYBKA, ANDREAS

<120> STABILIZED PEPTIDES

<130> P71215US0

<140> 10575864
<141> 2008-09-11

<150> PCT/EP04/11719
<151> 2004-10-18

<150> EP 03023395.1
<151> 2003-10-16

<160> 17

<170> PatentIn Ver. 3.3

<210> 1
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 11 and 18; See specification for detailed structure description

<400> 1
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Leu Gln
1 5 10 15

Met Cys Leu Asn Gly Ile Asn Asn
20

<210> 2
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 12, 15 and 19; See specification

for detailed structure description

<400> 2
Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Leu
1 5 10 15

Gln Met Cys Leu Asn Gly Ile Asn Asn
20 25

<210> 3
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 9, 13 and 16; See specification for detailed structure description

<400> 3
Ser Thr Lys Lys Thr Gln Leu Gln Gln Glu His Leu Gln Leu Asp Cys
1 5 10 15

Gln Met Ile Leu Asn Gly Ile Asn Asn
20 25

<210> 4
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 12, 15, 16 and 19; See specification for detailed structure description

<400> 4
Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Lys
1 5 10 15

Gln Met Cys Leu Asn Gly Ile Asn Asn
20 25

<210> 5
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 11 and 18; See specification
for detailed structure description

<400> 5
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Leu Gln
1 5 10 15

Met Cys Leu Asn Gly Ile Asn Asn
20

<210> 6
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 11 and 18; See specification
for detailed structure description

<220>
<221> MOD_RES
<222> (18)..(18)
<223> HomoCys

<400> 6
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Leu Gln
1 5 10 15

Met Xaa Leu Asn Gly Ile Asn Asn
20

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 11 and 18; See specification
for detailed structure description

<400> 7
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Asn Leu Leu Asp Leu Gln

```
  1               5                  10                  15

Met Cys Leu Asn Gly Ile Asn Asn
             20
```

<210> 8
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 11 and 18; See specification for detailed structure description

<220>
<221> MOD_RES
<222> (18)..(18)
<223> HomoCys

<400> 8

```
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Gln Leu Leu Asp Leu Gln
  1               5                  10                  15

Met Xaa Leu Asn Gly Ile Asn Asn
             20
```

<210> 9
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> Bridge linking positions 11 and 18; See specification for detailed structure description

<220>
<221> MOD_RES
<222> (18)..(18)
<223> HomoCys

<400> 9

```
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Lys Leu Leu Asp Leu Gln
  1               5                  10                  15

Met Xaa Leu Asn Gly Ile Asn Asn
             20
```

<210> 10
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 10 and 17; See specification
for detailed structure description

<400> 10
Ala Gln Gln Phe His Arg His Lys Gln Cys Ile Arg Phe Leu Lys Arg
1 5 10 15

Gln Asp Arg Asn Leu Trp Gly Leu Ala
20 25

<210> 11
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 14 and 21; See specification
for detailed structure description

<400> 11
Ala Gln Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Cys Lys Arg
1 5 10 15

Leu Asp Arg Asn Gln Trp Gly Leu Ala
20 25

<210> 12
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (19)..(19)
<223> HomoCys

<220>
<223> Bridge linking positions 19 and 26; See specification
for detailed structure description

<400> 12
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
1 5 10 15

Leu Glu Xaa Lys Glu Ala Glu Lys Ile Lys
20 25

<210> 13
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (12)..(12)
<223> HomoCys

<220>
<223> Bridge linking positions 12 and 19; See specification
for detailed structure description

<400> 13
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Xaa Glu Arg Tyr Leu
1 5 10 15

Leu Glu Lys Lys Glu Ala Glu Lys Ile Thr
20 25

<210> 14
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Bridge linking positions 9 and 16; See specification
for detailed structure description

<400> 14
Ser Thr Lys Lys Thr Gln Leu Gln Gln Glu His Leu Leu Leu Asp Cys
1 5 10 15

Gln Met Ile Leu Asn Gly Ile Asn Asn
20 25

<210> 15
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> HomoCys

<400> 15
Thr Lys Lys Thr Gln Leu Gln Leu Glu His Lys Leu Leu Asp Leu Gln
1 5 10 15

Met Xaa Leu Asn Gly Ile Asn Asn
20

<210> 16
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 16
Ala Gln Gln Phe His Arg His Gln Cys Ile Arg Phe Leu Lys Arg Gln
1 5 10 15

Asp Arg Asn Leu Trp Gly Leu Ala
20

<210> 17
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (19)..(19)
<223> HomoCys

<400> 17
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu

1 5 10 15

Leu Glu Xaa Lys Glu Ala Glu Lys Ile Lys
20 25